These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7906607)

  • 1. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.
    Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ
    Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis.
    Rubin SC; Finstad CL; Wong GY; Almadrones L; Plante M; Lloyd KO
    Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):162-9. PubMed ID: 8093588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.
    Skirnisdóttir I; Sorbe B; Seidal T
    Int J Gynecol Cancer; 2001; 11(2):119-29. PubMed ID: 11328410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer.
    Wong YF; Cheung TH; Lam SK; Lu HJ; Zhuang YL; Chan MY; Chung TK
    Gynecol Obstet Invest; 1995; 40(3):209-12. PubMed ID: 8529957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of prognostic significance of HER-2/neu in early epithelial ovarian cancer.
    Sueblinvong T; Manchana T; Khemapech N; Triratanachat S; Termrungruanglert W; Tresukosol D
    Asian Pac J Cancer Prev; 2007; 8(4):502-6. PubMed ID: 18260719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
    Berchuck A; Kamel A; Whitaker R; Kerns B; Olt G; Kinney R; Soper JT; Dodge R; Clarke-Pearson DL; Marks P
    Cancer Res; 1990 Jul; 50(13):4087-91. PubMed ID: 1972347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
    Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
    Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
    Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.
    Ross JS; Yang F; Kallakury BV; Sheehan CE; Ambros RA; Muraca PJ
    Am J Clin Pathol; 1999 Mar; 111(3):311-6. PubMed ID: 10078105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
    Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of Her2/Neu Protein Expression in Ovarian Epithelial Cancers.
    Jafri A; Rizvi S
    J Coll Physicians Surg Pak; 2017 Sep; 27(9):544-546. PubMed ID: 29017668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
    Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
    J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.
    Lee CH; Huntsman DG; Cheang MC; Parker RL; Brown L; Hoskins P; Miller D; Gilks CB
    Int J Gynecol Pathol; 2005 Apr; 24(2):147-52. PubMed ID: 15782071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms.
    Seidman JD; Frisman DM; Norris HJ
    Cancer; 1992 Dec; 70(12):2857-60. PubMed ID: 1360327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM; Werness BA; Mark HF
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
    Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
    Goff BA; Shy K; Greer BE; Muntz HG; Skelly M; Gown AM
    Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
    Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu expression: a major prognostic factor in endometrial cancer.
    Hetzel DJ; Wilson TO; Keeney GL; Roche PC; Cha SS; Podratz KC
    Gynecol Oncol; 1992 Nov; 47(2):179-85. PubMed ID: 1361478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.